Background The clinical impact of severe coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in immunocompromised …

Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …

Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …

Background Haematological malignancies and their treatments are likely to affect SARS-
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …

Despite therapeutic advances against SARS-CoV-2, including multiple vaccines, oral
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …